Does Rallies show Form 4 insider transactions for QURE?

Yes. Rallies tracks QURE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is QURE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for QURE. It does not provide personalized investment advice.

QURE (uniQure N.V.) Stock Analysis - Insider Trades

uniQure N.V. (QURE) is a publicly traded Healthcare sector company. As of May 21, 2026, QURE trades at $24.75 with a market cap of $1.57B and a P/E ratio of -7.01. QURE moved -0.45% today. Year to date, QURE is +8.71%; over the trailing twelve months it is +60.68%. Its 52-week range spans $4.45 to $71.50. Analyst consensus is buy with an average price target of $38.80. Rallies surfaces QURE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading QURE stock inside the company?

Recent QURE insider activity includes Abi-Saab Walid sold 25.00K, Abi-Saab Walid sold 20.00K, Kapusta Matthew C sold 14.58K, Abi-Saab Walid sold 808, and Potts Jeannette sold 3.41K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

QURE Key Metrics

Key financial metrics for QURE
Metric	Value
Price	$24.75
Market Cap	$1.57B
P/E Ratio	-7.01
EPS	$-3.48
Dividend Yield	0.00%
52-Week High	$71.50
52-Week Low	$4.45
Volume	57
Avg Volume	0
Revenue (TTM)	$18.09M
Net Income	$-208.87M
Gross Margin	90.56%

Recent QURE Insider Trades

Abi-Saab Walid sold 25.00K (~$627.50K) on May 8, 2026.
Abi-Saab Walid sold 20.00K (~$500.00K) on May 8, 2026.
Kapusta Matthew C sold 14.58K (~$132.10K) on Mar 4, 2026.
Abi-Saab Walid sold 808 (~$7.32K) on Mar 4, 2026.
Potts Jeannette sold 3.41K (~$30.91K) on Mar 4, 2026.

Latest QURE News

uniQure to File Q3 2026 AMT-130 UK MAA After 75% Huntington’s Slowing — Apr 30, 2026
uniQure Shares Rally as CBER Head Departs, AMT-130 Review Path May Open — Mar 9, 2026
uniQure Stock Soars 36% After FDA CBER Chief Resignation — Mar 9, 2026
uniQure Shares Surge Over 30% as FDA Biologics Chief Exits — Mar 9, 2026
UniQure Shares Surge 70% after FDA Division Chief Departure — Mar 7, 2026

QURE Analyst Consensus

12 analysts cover QURE: 0 strong buy, 8 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $38.80.

Common questions about QURE

Who is trading QURE stock inside the company?: Recent QURE insider activity includes Abi-Saab Walid sold 25.00K, Abi-Saab Walid sold 20.00K, Kapusta Matthew C sold 14.58K, Abi-Saab Walid sold 808, and Potts Jeannette sold 3.41K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for QURE?: Yes. Rallies tracks QURE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is QURE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for QURE. It does not provide personalized investment advice.